List of altered signaling pathways in DMD patients with ID versus in those without ID
| Term (upregulated in ID) | Counts | p-value | Benjamini | |||||
| DMD1 vs. DMD3 | DMD2 vs. DMD3 | DMD1 vs. DMD3 | DMD2 vs. DMD3 | DMD1 vs. DMD3 | DMD2 vs. DMD3 | |||
| hsa04390: Hippo signaling pathway | 12§ | 12§ | 6.E-04 | 1.E-03 | 2.E-02 | 3.E-01 | ||
| hsa04350:TGF-beta signaling pathway | 10 | 6 | 1.E-04 | 6.E-02 | 7.E-03 | 8.E-01 | ||
| hsa04610:Complement and coagulation cascades | 8 | 5 | 9.E-04 | 1.E-01 | 3.E-02 | 8.E-01 | ||
| hsa04310:Wnt signaling pathway | 10 | 9 | 4.E-03 | 2.E-02 | 7.E-02 | 7.E-01 | ||
| hsa04916:Melanogenesis | 7 | 8 | 3.E-02 | 1.E-02 | 3.E-01 | 8.E-01 | ||
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 8 | - | 3.E-02 | - | 3.E-01 | - | ||
| hsa00350:Tyrosine metabolism | 4 | 4 | 4.E-02 | 6.E-02 | 3.E-01 | 8.E-01 | ||
| Term (downregulated in ID) | Counts | p-value | Benjamini | |||||
| DMD1 vs. DMD3 | DMD2 vs. DMD3 | DMD1 vs. DMD3 | DMD2 vs. DMD3 | DMD1 vs. DMD3 | DMD2 vs. DMD3 | |||
| hsa04080: Neuroactive ligand-receptor interaction | 15§ | 30§ | 2.E-05 | 1.E-08 | 4.E-03 | 3.E-06 | ||
| hsa04924:Renin secretion | 6 | 14 | 2.E-03 | 9.E-08 | 1.E-01 | 9.E-06 | ||
| hsa00230:Purine metabolism | 8 | - | 1.E-02 | - | 3.E-01 | - | ||
| hsa04960:Aldosterone-regulated sodium reabsorption | 4 | 6 | 2.E-02 | 8.E-03 | 4.E-01 | 7.E-02 | ||
| hsa04022:cGMP-PKG signaling pathway | 7 | 12 | 3.E-02 | 2.E-02 | 4.E-01 | 1.E-01 | ||
| hsa04390:Hippo signaling pathway | 6 | - | 6.E-02 | - | 7.E-01 | - | ||
| hsa04270:Vascular smooth muscle contraction | 5 | 11 | 8.E-02 | 5.E-03 | 8.E-01 | 6.E-02 | ||
| hsa04020:Calcium signaling pathway | 6 | 15 | 1.E-01 | 2.E-03 | 8.E-01 | 2.E-02 | ||